BioXcel Therapeutics (BTAI) Accumulated Expenses (2017 - 2026)

BioXcel Therapeutics' Accumulated Expenses history runs 10 years deep, the most recent figure standing at $11000.0 for Q1 2026.

• In Q1 2026, Accumulated Expenses fell 99.72% year-over-year to $11000.0; the TTM figure through Mar 2026 stood at $11000.0 (down 99.72% YoY), while the FY2025 annual figure was $2.5 million, up 322.22% from the prior year.
• Accumulated Expenses was $11000.0 for Q1 2026 at BioXcel Therapeutics, down from $2.5 million in the prior quarter.
• In the past five years, Accumulated Expenses ranged from a high of $19.1 million in Q2 2023 to a low of $11000.0 in Q1 2026.
• Historically, Accumulated Expenses has averaged $5.5 million across 5 years, with a median of $3.3 million in 2022.
• The sharpest annual moves came in 2023 and 2026: Accumulated Expenses surged 472.35% in 2023, then tumbled 99.72% in 2026.
• A 5-year view of Accumulated Expenses shows it stood at $3.2 million in 2022, then jumped by 101.76% to $6.4 million in 2023, then tumbled by 90.59% to $603000.0 in 2024, then surged by 322.22% to $2.5 million in 2025, then sank by 99.57% to $11000.0 in 2026.
• The last three Accumulated Expenses figures came in at $11000.0 (Q1 2026), $2.5 million (Q4 2025), and $4.0 million (Q1 2025), per Business Quant data.